Adenosine Receptor Modulation

Adenosine Receptor Modulation designates pharmacological targeting of the four adenosine receptor subtypes, A1, A2A, A2B, and A3, which mediate diverse physiological effects including cardiac rhythm regulation, vasodilation, immune suppression, and neuroprotection through G-protein coupled signalling, representing therapeutic opportunities across cardiovascular, inflammatory, oncological, and neurological indications.

The biopharmaceutical industry has developed approved therapeutics exploiting adenosine receptor pharmacology, with A1 receptor agonists used as cardiac imaging agents and A2A receptor antagonists emerging as cancer immunotherapy partners reversing adenosine-mediated immune suppression in the tumour microenvironment. Tumours produce immunosuppressive adenosine creating an immunosuppressive microenvironment exploitable by A2A antagonists combined with checkpoint inhibitors. Cardiovascular applications target A1 receptors for rate control and A2B receptors in ischaemia-reperfusion protection. Neuroprotective applications explore A2A antagonism in Parkinson's disease and other neurodegenerative conditions. As understanding of adenosine receptor subtype selectivity and physiological roles deepens, more selective modulators continue advancing with improved therapeutic indices across diverse disease areas.